1828 / 1851
Toxicity of concurrent SRT and
antibody therapy
Anti-EGF-R (cetuximab)
Cetuximab + SRT studied
only in recurrent HNC (re-RT)
Considerable risk of severe toxicity (re-RT)
Not clear to which extent concurrent cetuximab
adds to the toxicity.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37